JP4823178B2 - クロマトグラフ迅速試験の測定範囲の拡張 - Google Patents
クロマトグラフ迅速試験の測定範囲の拡張 Download PDFInfo
- Publication number
- JP4823178B2 JP4823178B2 JP2007234331A JP2007234331A JP4823178B2 JP 4823178 B2 JP4823178 B2 JP 4823178B2 JP 2007234331 A JP2007234331 A JP 2007234331A JP 2007234331 A JP2007234331 A JP 2007234331A JP 4823178 B2 JP4823178 B2 JP 4823178B2
- Authority
- JP
- Japan
- Prior art keywords
- analyte
- test
- signal
- reaction time
- specific substance
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000012360 testing method Methods 0.000 title claims description 76
- 238000005259 measurement Methods 0.000 title claims description 39
- 239000012491 analyte Substances 0.000 claims description 123
- 230000035484 reaction time Effects 0.000 claims description 44
- 238000000034 method Methods 0.000 claims description 40
- 239000000126 substance Substances 0.000 claims description 37
- 238000003556 assay Methods 0.000 claims description 9
- 239000003153 chemical reaction reagent Substances 0.000 claims description 9
- 238000001514 detection method Methods 0.000 claims description 9
- 102400001263 NT-proBNP Human genes 0.000 claims description 8
- 108010008064 pro-brain natriuretic peptide (1-76) Proteins 0.000 claims description 8
- 239000003550 marker Substances 0.000 claims description 7
- 150000007523 nucleic acids Chemical class 0.000 claims description 6
- 108020004707 nucleic acids Proteins 0.000 claims description 6
- 102000039446 nucleic acids Human genes 0.000 claims description 6
- 239000003154 D dimer Substances 0.000 claims description 4
- 102000036675 Myoglobin Human genes 0.000 claims description 4
- 108010062374 Myoglobin Proteins 0.000 claims description 4
- 102000004987 Troponin T Human genes 0.000 claims description 4
- 108090001108 Troponin T Proteins 0.000 claims description 4
- 239000000427 antigen Substances 0.000 claims description 4
- 102000036639 antigens Human genes 0.000 claims description 4
- 108091007433 antigens Proteins 0.000 claims description 4
- 108010052295 fibrin fragment D Proteins 0.000 claims description 4
- 210000004369 blood Anatomy 0.000 claims description 3
- 239000008280 blood Substances 0.000 claims description 3
- 150000001720 carbohydrates Chemical class 0.000 claims description 3
- 235000014633 carbohydrates Nutrition 0.000 claims description 3
- 239000005556 hormone Substances 0.000 claims description 3
- 229940088597 hormone Drugs 0.000 claims description 3
- 150000002632 lipids Chemical class 0.000 claims description 3
- 239000002207 metabolite Substances 0.000 claims description 3
- 210000003205 muscle Anatomy 0.000 claims description 3
- 230000002644 neurohormonal effect Effects 0.000 claims description 3
- 230000003287 optical effect Effects 0.000 claims description 3
- 102000004856 Lectins Human genes 0.000 claims description 2
- 108090001090 Lectins Proteins 0.000 claims description 2
- 241000700605 Viruses Species 0.000 claims description 2
- 210000001124 body fluid Anatomy 0.000 claims description 2
- 239000010839 body fluid Substances 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 claims description 2
- 230000000302 ischemic effect Effects 0.000 claims description 2
- 239000002523 lectin Substances 0.000 claims description 2
- 244000005700 microbiome Species 0.000 claims description 2
- 210000002381 plasma Anatomy 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 108020003175 receptors Proteins 0.000 claims description 2
- 102000005962 receptors Human genes 0.000 claims description 2
- 210000003296 saliva Anatomy 0.000 claims description 2
- 210000002966 serum Anatomy 0.000 claims description 2
- 210000002700 urine Anatomy 0.000 claims description 2
- 238000001917 fluorescence detection Methods 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 description 14
- 230000000747 cardiac effect Effects 0.000 description 10
- 230000035945 sensitivity Effects 0.000 description 8
- 102100036836 Natriuretic peptides B Human genes 0.000 description 4
- 101710187802 Natriuretic peptides B Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 206010000891 acute myocardial infarction Diseases 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000012854 evaluation process Methods 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 108010023015 ischemia-modified albumin Proteins 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000007430 reference method Methods 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- OBHRVMZSZIDDEK-UHFFFAOYSA-N urobilinogen Chemical compound CCC1=C(C)C(=O)NC1CC1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(CC3C(=C(CC)C(=O)N3)C)N2)CCC(O)=O)N1 OBHRVMZSZIDDEK-UHFFFAOYSA-N 0.000 description 2
- 208000004476 Acute Coronary Syndrome Diseases 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 102000004420 Creatine Kinase Human genes 0.000 description 1
- 108010042126 Creatine kinase Proteins 0.000 description 1
- 102000030914 Fatty Acid-Binding Human genes 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000007390 Glycogen Phosphorylase Human genes 0.000 description 1
- 108010046163 Glycogen Phosphorylase Proteins 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- 108020001621 Natriuretic Peptide Proteins 0.000 description 1
- 102000004571 Natriuretic peptide Human genes 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 102000013394 Troponin I Human genes 0.000 description 1
- 108010065729 Troponin I Proteins 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- -1 antibodies Proteins 0.000 description 1
- 230000001746 atrial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 108091022862 fatty acid binding Proteins 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 239000002923 metal particle Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000004898 n-terminal fragment Anatomy 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 239000000692 natriuretic peptide Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000010118 platelet activation Effects 0.000 description 1
- 238000004451 qualitative analysis Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000012113 quantitative test Methods 0.000 description 1
- 239000002096 quantum dot Substances 0.000 description 1
- 238000002310 reflectometry Methods 0.000 description 1
- DUYSYHSSBDVJSM-KRWOKUGFSA-N sphingosine 1-phosphate Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)COP(O)(O)=O DUYSYHSSBDVJSM-KRWOKUGFSA-N 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54366—Apparatus specially adapted for solid-phase testing
- G01N33/54386—Analytical elements
- G01N33/54387—Immunochromatographic test strips
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5306—Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/557—Immunoassay; Biospecific binding assay; Materials therefor using kinetic measurement, i.e. time rate of progress of an antigen-antibody interaction
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06019008.9 | 2006-09-11 | ||
| EP06019008A EP1909206A1 (de) | 2006-09-11 | 2006-09-11 | Messbereichserweiterung chromatografischer Schnellteste |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008070366A JP2008070366A (ja) | 2008-03-27 |
| JP2008070366A5 JP2008070366A5 (enExample) | 2008-05-08 |
| JP4823178B2 true JP4823178B2 (ja) | 2011-11-24 |
Family
ID=37696091
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007234331A Active JP4823178B2 (ja) | 2006-09-11 | 2007-09-10 | クロマトグラフ迅速試験の測定範囲の拡張 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20080070234A1 (enExample) |
| EP (1) | EP1909206A1 (enExample) |
| JP (1) | JP4823178B2 (enExample) |
| CN (1) | CN101144810B (enExample) |
| CA (1) | CA2600221C (enExample) |
| ES (1) | ES2533467T3 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010017972A1 (en) * | 2008-08-13 | 2010-02-18 | Roche Diagnostics Gmbh | D-dimer, troponin, nt-probnp for pulmonary embolism |
| WO2014096184A1 (en) * | 2012-12-20 | 2014-06-26 | Roche Diagnostics Gmbh | Method for analyzing a sample of a body fluid |
| EP2936124B1 (en) * | 2012-12-20 | 2017-03-15 | Roche Diabetes Care GmbH | Methods for evaluating medical measurement curves |
| CN104714025B (zh) * | 2014-11-28 | 2017-05-17 | 威海纽普生物技术有限公司 | NT‑proBNP检测试剂盒及检测方法 |
| CN107505299A (zh) * | 2017-09-04 | 2017-12-22 | 中国人民解放军第三军医大学 | 一种从尿液中检测骨骼肌微损伤标志物肌红蛋白的方法 |
| KR20190076624A (ko) * | 2017-12-22 | 2019-07-02 | 삼성전자주식회사 | 검사 장치 및 그 제어방법 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2946850B2 (ja) * | 1991-06-30 | 1999-09-06 | 株式会社島津製作所 | 抗原抗体反応におけるプロゾーン判定方法及び分析方法 |
| FR2693213B1 (fr) | 1992-07-03 | 1994-08-05 | Kaysersberg Sa | Procede destine a diminuer l'interaction entre fibres dans un tissue et mise en óoeuvre de ce procede, notamment pour fabriquer des tissues multi-strates. |
| JPH0696697A (ja) | 1992-09-11 | 1994-04-08 | Hitachi Ltd | カラー陰極線管 |
| US5756362A (en) * | 1993-10-12 | 1998-05-26 | Cornell Research Foundation, Inc. | Liposome-enhanced immunoaggregation assay and test device |
| JPH0875740A (ja) * | 1994-08-31 | 1996-03-22 | Shimadzu Corp | 免疫比濁分析方法 |
| US6830731B1 (en) * | 1998-01-05 | 2004-12-14 | Biosite, Inc. | Immunoassay fluorometer |
| EP1151304B9 (de) * | 1999-01-29 | 2008-06-04 | Roche Diagnostics GmbH | VERFAHREN ZUM NACHWEIS VON N-TERMINALEM proBNP |
| JP3726082B2 (ja) * | 2000-12-26 | 2005-12-14 | 松下電器産業株式会社 | 特異結合分析方法およびそれに用いる特異結合分析装置 |
| EP1416276B1 (en) * | 2001-08-09 | 2007-03-07 | Matsushita Electric Industrial Co., Ltd. | Biosensors and measurement method |
| EP1361435A4 (en) * | 2001-09-28 | 2005-01-26 | Matsushita Electric Industrial Co Ltd | ANALYZER AND PROCESS FOR SPECIFIC BINDING |
| WO2003056312A1 (en) * | 2001-12-27 | 2003-07-10 | Arkray, Inc. | Concentration measuring method |
| ATE339687T1 (de) * | 2002-05-22 | 2006-10-15 | Sysmex Corp | Immunologische verfahren, vorrichtungen und reagenzien |
| AU2003302340B8 (en) * | 2002-12-24 | 2008-09-11 | Biosite Incorporated | Markers for differential diagnosis and methods of use thereof |
| US20050250141A1 (en) * | 2004-03-30 | 2005-11-10 | Lambert James L | Diagnostic assays including multiplexed lateral flow immunoassays with quantum dots |
| DE102004023402A1 (de) * | 2004-05-12 | 2005-12-08 | Roche Diagnostics Gmbh | Verfahren zur Erhöhung des dynamischen Messbereichs von auf spezifischen Bindereaktionen basierenden, insbesondere immunologischen Testelementen |
| JP4805564B2 (ja) * | 2004-10-22 | 2011-11-02 | シスメックス株式会社 | 生体試料分析装置および方法 |
| US20080206782A1 (en) * | 2005-03-08 | 2008-08-28 | Genentech, Inc. | Methods for Determining the Bivalency of Protein and Antibody Therapeutics |
-
2006
- 2006-09-11 EP EP06019008A patent/EP1909206A1/de not_active Ceased
-
2007
- 2007-09-06 CA CA2600221A patent/CA2600221C/en not_active Expired - Fee Related
- 2007-09-10 JP JP2007234331A patent/JP4823178B2/ja active Active
- 2007-09-10 ES ES07017673.0T patent/ES2533467T3/es active Active
- 2007-09-11 US US11/853,100 patent/US20080070234A1/en not_active Abandoned
- 2007-09-11 CN CN200710148772XA patent/CN101144810B/zh active Active
-
2014
- 2014-07-14 US US14/330,179 patent/US9285376B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2600221A1 (en) | 2008-03-11 |
| ES2533467T3 (es) | 2015-04-10 |
| US20080070234A1 (en) | 2008-03-20 |
| CN101144810A (zh) | 2008-03-19 |
| JP2008070366A (ja) | 2008-03-27 |
| US20140322703A1 (en) | 2014-10-30 |
| CN101144810B (zh) | 2012-12-05 |
| EP1909206A1 (de) | 2008-04-09 |
| US9285376B2 (en) | 2016-03-15 |
| CA2600221C (en) | 2017-05-30 |
| HK1118608A1 (en) | 2009-02-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4423463B2 (ja) | 濃度測定方法 | |
| US9285376B2 (en) | Measuring range extension of chromatographic rapid tests | |
| JP6396857B2 (ja) | 少量の体液試料中のマーカーを判定する方法 | |
| JP3424831B2 (ja) | 結合アッセイ | |
| EP2843414B1 (en) | Marker for statin treatment stratification in heart failure | |
| US11747328B2 (en) | Method for measuring the plasma concentration of an analyte directly on a whole blood sample | |
| JP2008070366A5 (enExample) | ||
| JP2018522219A (ja) | 電磁放射線を使用した分析物の検出方法 | |
| JP2010528306A (ja) | 心筋梗塞の早期予測因子としてのh−fabp | |
| JP5307141B2 (ja) | 心筋梗塞の早期予測因子としてのミオグロビン | |
| HK1118608B (en) | Measuring range extension of chromatographic rapid tests | |
| JP6282436B2 (ja) | 虚血性心疾患の評価方法、評価用キット及び評価装置 | |
| RU2480772C1 (ru) | Способ одновременного детектирования тиротропина и общего тироксина в сухих пятнах крови | |
| KR101594379B1 (ko) | 면역크로마토그래피를 이용한 히스티딘-태그를 가진 단백질 검출방법 | |
| EP4086633B1 (en) | Prognostic method | |
| JP4606643B2 (ja) | 分析対象物を定量する方法 | |
| JP2011038858A (ja) | 血栓症の早期診断のための検査方法と検査試薬およびキット | |
| EP1909207B1 (de) | Messbereichserweiterung chromatografischer Schnellteste | |
| Swaanenburg et al. | Analytical aspects of the automated CKMB1, 2 and CKMM1, 2, 3 isoform determination and its relation to other biochemical markers | |
| Swaanenburg | The biochemical and clinical assessment of cardiac markers for the detection of various forms of myocardial tissue damage | |
| HK1177782A (en) | A method for determining a marker in small volume of a sample of a bodily fluid |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080130 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080130 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20100611 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100615 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20101130 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110228 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110329 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20110830 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20110906 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 4823178 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140916 Year of fee payment: 3 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |